Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
- **Hydroxychloroquine** is an antimalarial and disease-modifying anti-rheumatic drug (DMARD) that modulates immune system activity, reducing inflammation. It is used in the treatment of malaria, rheumatoid arthritis, and lupus erythematosus. Its mechanism involves interfering with lysosomal activity and antigen presentation in immune cells[1][6][7]. - **Paracetamol** (also known as acetaminophen) is an analgesic and antipyretic agent commonly used to relieve mild to moderate pain and reduce fever. It acts primarily by inhibiting prostaglandin synthesis in the central nervous system. - **Prednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to glucocorticoid receptors, modulating gene expression to suppress inflammatory responses[2][5]. This combination may be considered for conditions where both immunomodulation/anti-inflammation (hydroxychloroquine, prednisolone) and symptomatic relief of pain or fever (paracetamol) are required—such as autoimmune diseases like rheumatoid arthritis or lupus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxychloroquine + paracetamol + prednisolone.